GALVUS NOVARTIS PDF

Novartis’ Galvus (vildagliptin) is a member of a new class of oral antidiabetic agents known as dipeptidyl peptidase IV inhibitors (DPP-IV) inhibitors or ‘incretin . Galvus Approval Status. FDA Approved: No Brand name: Galvus Generic name: vildagliptin. Previous Name: LAF Company: Novartis Pharmaceuticals. Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral.

Author: Shaktishakar JoJogis
Country: Mauritania
Language: English (Spanish)
Genre: Technology
Published (Last): 2 September 2010
Pages: 440
PDF File Size: 8.69 Mb
ePub File Size: 3.64 Mb
ISBN: 176-6-75854-800-7
Downloads: 84213
Price: Free* [*Free Regsitration Required]
Uploader: Gajind

At mg, there were three cases of muscle pain, and individual cases of mild and transient paraesthesia, fever, oedema and a transient increase in lipase levels. Oxandrolone Oxandrolone may increase the hypoglycemic activities of Vildagliptin. Icandra is used to treat adults with type-2 diabetes. Flumequine The therapeutic efficacy onvartis Vildagliptin can be increased when used in combination with Flumequine.

Lacidipine The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Vildagliptin. Moexiprilat The risk or severity of angioedema can be increased when Vildagliptin is combined with Moexiprilat. Cyclothiazide The therapeutic efficacy of Vildagliptin can be increased when novarrtis in combination with Cyclothiazide.

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfaphenazole. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfaguanidine. The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Vildagliptin.

Vildagliptin – DrugBank

The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ceritinib. Adverse reactions reported in patients who received Galvus in double-blind studies as monotherapy and add-on therapies are listed below for each indication by system organ class and absolute frequency.

  KRUSEMAN AND DE RIDDER PDF

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Furosemide. The risk or severity of angioedema can be increased when Urokinase is combined with Vildagliptin. Urokinase The risk or severity of angioedema can be increased when Urokinase is combined with Vildagliptin. The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Vildagliptin.

The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Vildagliptin. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Etonogestrel. Reporting suspected adverse reactions after authorisation of the medicinal product is important. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Clorsulon.

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Fasudil.

Amitriptylinoxide Amitriptylinoxide may decrease the hypoglycemic activities of Vildagliptin. The incidence of peripheral oedema was lower novartus the vildagliptin group than in the rosiglitazone group 2. Nalidixic acid The therapeutic efficacy of Vildagliptin can be increased when used in combination with Nalidixic Acid.

The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Vildagliptin. Glisoxepide Vildagliptin may increase the hypoglycemic activities of Glisoxepide. Omarigliptin The risk or severity of angioedema can be increased when Vildagliptin is combined with Omarigliptin.

Vildagliptin launched by Novartis for dual therapy in type 2 diabetes

Three other subjects experienced oedema of the feet, with paraesthesia in two cases. Mestranol The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Mestranol. The gavlus efficacy of Vildagliptin can be decreased when used in combination with Prednisone. Ciprofloxacin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Ciprofloxacin. Trimipramine Trimipramine may decrease the hypoglycemic activities of Vildagliptin.

Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue Galvus.

  MACGOURMET IMPORT PDF

Clinical trials of up to more than 2 years’ duration did not show any additional safety signals or unforeseen risks when vildagliptin was added on to metformin. As triple oral therapy in combination with – a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. Sulfaperin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfaperin.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) | European Medicines Agency

It can be used in conjunction with the previous volume or on its own. The incidence of hypoglycaemia was similar in both treatment groups Simeprevir The therapeutic efficacy of Novarrtis can be increased when used in combination with Simeprevir. Fluticasone The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Fluticasone.

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Clofenamide.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis)

Vildagliptin belongs to a class of orally active antidiabetic drugs DPP-IV inhibitors that appear to have multiple functional benefits beyond simple blood-glucose control. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Chlorothiazide.

Icandra is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.

Iprindole Iprindole may decrease the hypoglycemic activities of Vildagliptin. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfachlorpyridazine.

VPN